GeoVax Labs (NASDAQ:GOVX) Posts Earnings Results, Beats Estimates By $0.88 EPS

GeoVax Labs (NASDAQ:GOVX) announced its quarterly earnings data on Thursday. The company reported ($2.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.50) by $0.88, FiscalAI reports.

GeoVax Labs Stock Down 3.1%

NASDAQ GOVX traded down $0.04 during trading hours on Thursday, reaching $1.26. The company’s stock had a trading volume of 125,676 shares, compared to its average volume of 213,543. The firm’s 50-day moving average price is $1.42 and its 200-day moving average price is $4.84. GeoVax Labs has a 1 year low of $0.96 and a 1 year high of $34.75. The company has a market capitalization of $3.65 million, a price-to-earnings ratio of -0.04 and a beta of 3.36.

Wall Street Analysts Forecast Growth

GOVX has been the subject of a number of recent research reports. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Tuesday, April 21st. Finally, Wall Street Zen downgraded GeoVax Labs to a “strong sell” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $150.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new position in GeoVax Labs in the 4th quarter worth approximately $99,000. Renaissance Technologies LLC purchased a new position in GeoVax Labs in the 4th quarter worth approximately $104,000. Armistice Capital LLC purchased a new position in GeoVax Labs in the 3rd quarter worth approximately $253,000. Finally, HRT Financial LP purchased a new stake in shares of GeoVax Labs during the 4th quarter worth approximately $31,000. 6.09% of the stock is owned by hedge funds and other institutional investors.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.